236results about "Muscle proteins" patented technology

The disclosure provides polynucleotides containing regions of the Myosin 15 (Myo15) promoter, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss or vestibular dysfunction.

The disclosure provides polynucleotides containing regions of the Myosin 15 (Myo15) promoter, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss or vestibular dysfunction.

Described herein are muscle-specific targeting moieties and compositions including the muscle specific targeting motifs. Also described herein are uses of the muscle-specific targeting motifs and compositions including the muscle specific targeting moieties. In some embodiments, the muscle-specific targeting moieties and compositions including the muscle specific targeting moieties can be used to direct delivery of a cargo to a muscle cell.

The invention belongs to the field of medicines, and discloses application of a stress-induced stem cell extract in treatment of cerebral apoplexy. The inventor finds that stem cells are cultured under proper stress conditions through screening, and the separated stem cell extract (also known as Alritoin) can increase the axon length and dendritic length of normal primary neurons and is beneficial to growth and conduction of nerve fibers; in a pdMCAO model, the volume of cerebral infarction in the acute stage of ischemia of a mouse can be remarkably reduced, the neurological function score can be improved, and a relatively good improvement trend is achieved in the aspect of cognition; in the acute stage of cerebral ischemia reperfusion, the pharmaceutical composition has remarkable effects on reducing the cerebral infarction volume of a mouse, reducing relative edema and improving the neurological function, and is relatively long in medication time window; in a cerebral ischemia reperfusion model, the trend of improving local cerebral blood flow is shown. The allitoin is expected to be developed into a promising drug for cerebral apoplexy, especially a drug for treating ischemic cerebral apoplexy.

Compositions and methods for using actin-based peptides to modulate cellular bioactivity. including modulation of cellular susceptibility to intracellular pathogens, such as bacteria and viruses.

The invention belongs to the field of biological medicines, and discloses an application of a protein polymer in preparation of a medicine for treating Alzheimer's disease, a production process of the protein polymer comprises the following steps: S1) using ultraviolet irradiation to stimulate mesenchymal stem cells and culturing; and S2) splitting the mesenchymal stem cells, separating and purifying to obtain the protein polymer. According to the present invention, the mesenchymal stem cells are stimulated to express the protein with the nerve repair function through the ultraviolet irradiation stress mode, and the protein polymer is obtained through further separation and purification, such that the protein polymer can be adapted to diversified application modes, can improve the abnormal conditions of the Alzheimer's disease related biomarkers, and can provide the significant treatment effect on the Alzheimer's disease.

The invention belongs to the field of tuberculosis diagnosis, and particularly relates to an application of a KNCN recombinant protein in tuberculosis diagnosis. The KNCN recombinant protein can specifically and efficiently capture various tuberculosis antigens, the KNCN protein can capture several tuberculosis antigens in a tuberculosis patient specimen at the same time, and by expressing and purifying the recombinant KNCN protein, the captured binding antigen is detected.

Disclosed herein are adapted dystrophin proteins (e.g., adapted mini- or micro-dystrophin proteins), nucleic acid molecules and vectors encoding the same, as well as methods of treating a muscular dystrophy (e.g., Duchenne or Becker muscular dystrophy), for example by gene therapy comprising the adapted dystrophin proteins, the nucleic acid molecules, or the vectors of the disclosure.

The invention belongs to the field of biological medicines, and discloses an application of a protein polymer in preparation of a medicine for treating spinal cerebellar ataxia disease, a production process of the protein polymer comprises the following steps: S1) using ultraviolet irradiation to stimulate mesenchymal stem cells and culturing; and S2) splitting the mesenchymal stem cells, separating and purifying to obtain the protein polymer. An ultraviolet irradiation stress mode is adopted, mesenchymal stem cells are stimulated to express protein with a neural repair function, the protein polymer is obtained through further separation and purification, the cell gene expression pathway is regulated, the cell stress state is relieved, the cells are promoted to recover normal forms and functions, meanwhile, the preparation mode is relatively simple, and the preparation method is suitable for large-scale production. And quality and yield monitoring is facilitated, and the method can be adapted to diversified application modes.

The present disclosure relates to compositions and methods of treating stroke, reducing neuroinflammation, and generating new neurons in a primate using an adeno-associated viral (AAV) vector encoding NeuroD1.

Provided herein are gene therapy compositions and methods for treating reduced levels of functional cardiac myosin binding protein C in a subject suffering from hypertrophic cardiomyopathy.

Recombinant myotropic AAV rh.74 capsids are described herein. In addition, plasmids, viral vectors, dual vector systems, cells, and compositions comprising or encoding such recombinant capsids are further described. Such recombinant polynucleotides, plasmids, viral vectors, dual vector systems, cells, and compositions may be used to treat muscle diseases or disorders, including muscular dystrophies and cardiomyopathies.

Provided is a TRIM72 truncated protein, comprising the Coiled-PRYSPRY domain or PRYSPRY domain or its functional fragment of a TRIM72 protein. Further provided is the use of the TRIM72 truncated protein.

The present disclosure relates to compositions and methods for the treatment of cardiomyopathy. Several embodiments provided for herein relate to virally-mediated transfer of a gene to host cells to induce expression of an encoded polypeptide, protein or other product to host in order to ameliorate one or more symptoms of the cardiomyopathy. In several embodiments, the methods and compositions relate to recombinant adeno-associated virus particles encoding human TNNT2 in order to treat cardiomyopathies, including dilated cardiomyopathy or hypertrophic cardiomyopathy.

The present invention provides antigen-binding molecules, specifically domain-engineered antibodies in which at least one constant region domain, CH1 / CL, is replaced with Titin T chain / Obscurin-O chain.

Aspects of the disclosure relate to compositions and methods useful for delivering minigenes to a subject. Accordingly, the disclosure is based, in part, on isolated nucleic acids and gene therapy vectors, such as viral (e.g., rAAV) vectors, comprising one or more gene fragments encoding a therapeutic gene product, such as a protein or peptide (e.g. a minigene). In some embodiments, the disclosure relates to gene therapy vectors encoding a USH1B protein (e.g. the gene product of USH1B, also referred to as MY07A) or a portion thereof. In some embodiments, compositions described by the disclosure are useful for treating diseases associated with mutations in the USH1B (MY07A) gene, for example Usher Syndrome.

Nucleotide sequences including a micro-dystrophin gene are provided. The micro-dystrophin genes may be operatively linked to a regulatory cassette. Methods of treating a subject having, or at risk of developing, muscular dystrophy, sarcopenia, heart disease, or cachexia are also provided. The methods may include administering a pharmaceutical composition including the micro-dystrophin gene and a delivery vehicle to a subject. Further, the methods may include administering the pharmaceutical composition a subject having Duchenne muscular dystrophy or Becker muscular dystrophy.

Synthetic nucleic acids encoding mini and microdystrophin genes comprising the membrane binding motifs or domains of the R10-R11-R12 region are provided. Also provided are vectors, host cells, and related methods of using the same to treat a subject suffering from Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) or X-linked dilated cardiomyopathy (XLDC), or for ameliorating one or more adverse effects of DMD, BMD, or XLDC. Also provided are a fusion protein comprising a nNOS binding domain of dystrophin R16-R17 that is operably linked to a syntrophin PDZ domain and synthetic nucleic acids comprising the same that can be used to treat subjects with diseases characterized by loss of sarcolemmal neuronal nitric oxide synthase (nNOS) activity.

The present disclosure relates to methods of treating conditions associated with a requirement for merlin protein, for example due to a defective neurofibromin 2 / merlin (NF2) gene, such as in neurofibromatosis type 2 (NF2). Specifically, the present disclosure provides gene therapy vectors that specifically treat loss of expression of merlin protein or reduced levels of merlin protein.

Recombinant myotropic AAV rh.74 capsids are described herein. In addition, plasmids, viral vectors, dual vector systems, cells, and compositions comprising or encoding such recombinant capsids are further described. Such recombinant polynucleotides, plasmids, viral vectors, dual vector systems, cells, and compositions may be used to treat muscle diseases or disorders, including muscular dystrophies and cardiomyopathies.

The invention belongs to the technical field of food detection, and discloses an immunoaffinity column of tropomyosin, a preparation method and an application thereof. The immunoaffinity column of tropomyosin comprises a carrier and a tropomyosin antibody, wherein the antibody is an antibody produced by immunization of tropomyosin of white shrimp, and tropomyosin is a protein obtained by extraction and purification of white shrimp; the tropomyosin antibody is coupled to the carrier by a chemical bond, and the tropomyosin antibody is cross-linked with a cross-linking agent after being combined with the carrier. The affinity column of the invention utilizes a chemically modified solid phase carrier, and then tropomyosin is covalently coupled to the carrier to load the affinity column. The immunoaffinity column is mainly used for the purification of tropomyosin, an allergen in crustacean-containing foods, so as to facilitate the detection of tropomyosin in samples at a later stage. The immunoaffinity column of the invention has the advantages of being fast, simple, accurate, having good specificity and high sensitivity for the detection of tropomyosin in food, and provides a powerful means for food inspection and analysis.

The invention belongs to the technical field of genetic engineering, and particularly relates to truncated tropomyosin, a nucleic acid molecule and application of the truncated tropomyosin. The truncated tropomyosin is based on an alpha-helical structure of tropomyosin, and is obtained by taking glutamic acid (E26) at the 26th site, glutamine (Q51) at the 51st site or glutamic acid (E73) at the 73rd site as a truncation site. By reasonably designing a truncation site and further replacing the secretion signal peptide, the expression quantity of the protein in a recombinant expression system is remarkably improved, the immunogenicity of the protein is effectively reserved, and the protein can be used for precise diagnosis of allergy and development of anti-allergic vaccines.

Nucleotide sequences including a micro-dystrophin gene are provided. The micro-dystrophin genes may be operatively linked to a regulatory cassette. Methods of treating a subject having, or at risk of developing, muscular dystrophy, sarcopenia, heart disease, or cachexia are also provided. The methods may include administering a pharmaceutical composition including the micro-dystrophin gene and a delivery vehicle to a subject. Further, the methods may include administering the pharmaceutical composition a subject having Duchenne muscular dystrophy or Becker muscular dystrophy.

The present invention relates to the field of biomedicine technology, and in particular to an α-myosin mutant and its application. Lysine (K) at position 1897 in the wild-type Myh6 protein is mutated to arginine (R). The nucleotide sequence corresponding to the wild-type Myh6 protein is shown in the bases in SEQ ID NO.1. Application of α-myosin mutants as Ang II-induced heart failure pathology models. The present invention obtains α-myosin mutants through the gene editing method of the CRISPR / Cas9 system, confirms that the 1897 site in α-myosin participates in and regulates the degree of interaction between α-MHC and Titin, thereby reflecting the degree of heart failure. The obtained α-myosin mutant is used as a pathology model leading to heart failure, which can lay the foundation for the study of organic heart failure, especially heart failure caused by abnormal myofilament structure.

In some embodiments, the present disclosure relates to nucleic acids, compositions and methods for delivering therapeutic genes to a subject. In some embodiments, the therapeutic genes are delivered via the use of viral vectors. In some embodiments, the viral vector is an adeno-associated virus. In some embodiments, the therapeutic genes are delivered to treat heart disease, injury or other disorders.

Nucleic acid molecules comprising at least one transcription regulatory element operably linked to an open reading frame, wherein the open reading frame encodes a single RNA transcript encoding GCaMP7f, a ribosomal skipping peptide, and a fusion protein of a nuclear protein and photoactivatable red fluorescent protein are provided. Expression vectors and cells comprising the nucleic acid molecules are also provided, as are methods of using the nucleic acid molecules for simultaneous labeling and measuring calcium and analyzing a target cell.

The present disclosure provides lentiviral vectors comprising a nucleic acid sequence encoding MyoVIIa isoform 1 for treatment of Usher 1B syndrome in a subject in need thereof. In some embodiments, treatment of Usher 1B syndrome comprises amelioration of presbycusis caused by heterozygous mutations in MyoVIIa and / or balance problems caused by homozygous mutations in MyoVIIa.

In several embodiments, the present disclosure relates to nucleic acids, compositions, and methods for the delivery of a therapeutic gene to a subject. In several embodiments, the therapeutic gene is through the use of a viral vector. In several embodiments, the viral vector is an adeno-associated virus. In several embodiments, the therapeutic gene is delivered to treat a cardiac disease, injury or other disorder.

Disclosures herein are directed to compositions comprising single guide RNA (sgRNA) and fusion proteins comprising a Cas9 nickase and deaminase designed for a CRISPR-Cas9 system and method of using thereof for preventing, ameliorating or treating one or more cardiomyopathies.

The present invention discloses an umami peptide derived from Portunus trituberculatus and an application thereof, and belongs to the technical field of bioactive peptides. An amino acid sequence of the umami peptide derived from the Portunus trituberculatus is SGSFK, as shown in SEQ ID NO. 4. The umami peptide derived from the Portunus trituberculatus is used as or in preparation of an umami agent. The present invention integrates virtual enzymatic hydrolysis, screening and docking technologies to extract the umami peptide from the Portunus trituberculatus. Through sensory evaluation and electronic tongue analysis, it has been verified that the umami peptide SGSFK in the present invention is more umami than monosodium glutamate at a same concentration, and has an umami threshold of 0.125 mg / ml. The present invention provides a new raw material basis for development of umami agents and condiments, and has good application prospects and important application value.